The aim was to clarify, in the absence of any other pathophysiological condition, whether visfatin/eNampt was capable to induce by itself endothelial dysfunction and vascular inflammation in a more complex environment and after a sustained non-acute infusion. The gene discussed is NAMPT; the disease is endothelial dysfunction.